Surgical Science Sweden AB (publ) (STO:SUS)
Sweden
· Delayed Price · Currency is SEK 159.40
-0.70 (-0.44%)
Feb 21, 2025, 5:29 PM CET
STO:SUS Revenue
In the year 2024, Surgical Science Sweden AB had annual revenue of 884.09M SEK with 0.14% growth. Surgical Science Sweden AB had revenue of 251.55M in the quarter ending December 31, 2024, with 10.67% growth.
Revenue
884.09M
Revenue Growth
+0.14%
P/S Ratio
9.20
Revenue / Employee
3.23M
Employees
260
Market Cap
8.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 884.09M | 1.23M | 0.14% |
| Dec 31, 2023 | 882.85M | 80.31M | 10.01% |
| Dec 31, 2022 | 802.54M | 435.76M | 118.81% |
| Dec 31, 2021 | 366.78M | 261.98M | 249.98% |
| Dec 31, 2020 | 104.80M | 3.28M | 3.23% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.03B |
| Getinge AB | 34.76B |
| Sectra AB | 3.14B |
| Camurus AB | 1.87B |
| Medicover AB | 23.97B |
| Vitrolife AB | 3.61B |
| Elekta AB | 17.88B |
| Vimian Group AB | 4.29B |